Back to News
Market Impact: 0.2
The Next Chapter of B7-H3: From Systemic Disease to the Brain
Source: PR Newswire
Healthcare & BiotechTechnology & Innovation
T-MAXIMUM presented early data for its B7-H3 allogeneic CAR-T program targeting brain metastases at WCLC 2026. The provided article excerpt does not disclose efficacy, safety, patient-enrollment, or financial results, limiting assessment of the program's clinical and valuation implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- AMD joins the $1 trillion club as chip rally surges - our AI Strategy saw it early
- Here's who we know is going to the Trump-Xi dinner so far
- +17% in a single session: This AI-picked stock catches a data-center breakout
- Asia stocks rise tracking U.S. tech rally; Trump-Xi meeting eyed
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club